Need Assistance?
  • US & Canada:
    +
  • UK: +

CPF-B1

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

CPF-B1 is produced by Xenopus borealis. The peptide with the greatest potential for development into a therapeutically valuable anti-infective agent was CPF-B1 with MIC=5 microM against E. coli, MIC=5 microM against S. aureus, and MIC=25 microM against Candida albicans, and low hemolytic activity against human erythrocytes (LC(50)>200 microM).

Category
Functional Peptides
Catalog number
BAT-013460
Molecular Formula
C126H218N36O34S2
Molecular Weight
2845.4
IUPAC Name
(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]acetyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid
Synonyms
GLGSLLGKAFKIGLKTVGKMMGGAPREQ; CPF-B1
Sequence
GLGSLLGKAFKIGLKTVGKMMGGAPREQ
InChI
InChI=1S/C126H218N36O34S2/c1-18-72(12)103(160-114(184)79(36-24-28-48-129)150-118(188)90(58-76-32-20-19-21-33-76)156-105(175)73(13)143-109(179)77(34-22-26-46-127)144-97(169)62-139-108(178)87(55-68(4)5)157-117(187)89(57-70(8)9)158-119(189)91(66-163)148-100(172)63-138-107(177)86(54-67(2)3)146-94(166)59-131)122(192)141-65-99(171)147-88(56-69(6)7)116(186)149-80(37-25-29-49-130)115(185)161-104(75(15)164)123(193)159-102(71(10)11)121(191)140-64-98(170)145-78(35-23-27-47-128)110(180)153-84(45-53-198-17)113(183)152-83(44-52-197-16)106(176)137-60-95(167)136-61-96(168)142-74(14)124(194)162-51-31-39-92(162)120(190)154-81(38-30-50-135-126(133)134)111(181)151-82(41-43-101(173)174)112(182)155-85(125(195)196)40-42-93(132)165/h19-21,32-33,67-75,77-92,102-104,163-164H,18,22-31,34-66,127-131H2,1-17H3,(H2,132,165)(H,136,167)(H,137,176)(H,138,177)(H,139,178)(H,140,191)(H,141,192)(H,142,168)(H,143,179)(H,144,169)(H,145,170)(H,146,166)(H,147,171)(H,148,172)(H,149,186)(H,150,188)(H,151,181)(H,152,183)(H,153,180)(H,154,190)(H,155,182)(H,156,175)(H,157,187)(H,158,189)(H,159,193)(H,160,184)(H,161,185)(H,173,174)(H,195,196)(H4,133,134,135)/t72-,73-,74-,75+,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,102-,103-,104-/m0/s1
InChI Key
RJFWHUPUGURVHZ-ALGBRYTKSA-N
Canonical SMILES
CCC(C)C(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCSC)C(=O)NC(CCSC)C(=O)NCC(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CN
1. Antimicrobial peptides with therapeutic potential from skin secretions of the Marsabit clawed frog Xenopus borealis (Pipidae)
Milena Mechkarska, Eman Ahmed, Laurent Coquet, Jérôme Leprince, Thierry Jouenne, Hubert Vaudry, Jay D King, J Michael Conlon Comp Biochem Physiol C Toxicol Pharmacol. 2010 Nov;152(4):467-72. doi: 10.1016/j.cbpc.2010.07.007. Epub 2010 Jul 23.
Nine peptides with differential growth inhibitory activity against Escherichia coli and Staphylococcus aureus were isolated from norepinephrine-stimulated skin secretions of the tetraploid frog Xenopus borealis Parker, 1936 (Pipidae). Structural characterization of the peptides demonstrated that they were orthologous to magainin-2 (1 peptide), peptide glycine-leucine-amide, PGLa (2 peptides), caerulein-precursor fragments, CPF (4 peptides), and xenopsin-precursor fragments, XPF (2 peptides), previously isolated from Xenopus laevis and X. amieti. In addition, a second magainin-related peptide (G**KFLHSAGKFGKAFLGEVMIG) containing a two amino acid residue deletion compared with magainin-2 was identified that had only weak antimicrobial activity. The peptide with the greatest potential for development into a therapeutically valuable anti-infective agent was CPF-B1 (GLGSLLGKAFKIGLKTVGKMMGGAPREQ) with MIC=5 microM against E. coli, MIC=5 microM against S. aureus, and MIC=25 microM against Candida albicans, and low hemolytic activity against human erythrocytes (LC(50)>200 microM). This peptide was also the most abundant antimicrobial peptide in the skin secretions. CPF-B1 was active against clinical isolates of the nosocomial pathogens, methicillin-resistant S. aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDRAB) with MIC values in the range 4-8 microM.
2. Large scale ab initio modeling of structurally uncharacterized antimicrobial peptides reveals known and novel folds
Mara Kozic, Stephen J Fox, Jens M Thomas, Chandra S Verma, Daniel J Rigden Proteins. 2018 May;86(5):548-565. doi: 10.1002/prot.25473. Epub 2018 Feb 18.
Antimicrobial resistance within a wide range of infectious agents is a severe and growing public health threat. Antimicrobial peptides (AMPs) are among the leading alternatives to current antibiotics, exhibiting broad spectrum activity. Their activity is determined by numerous properties such as cationic charge, amphipathicity, size, and amino acid composition. Currently, only around 10% of known AMP sequences have experimentally solved structures. To improve our understanding of the AMP structural universe we have carried out large scale ab initio 3D modeling of structurally uncharacterized AMPs that revealed similarities between predicted folds of the modeled sequences and structures of characterized AMPs. Two of the peptides whose models matched known folds are Lebocin Peptide 1A (LP1A) and Odorranain M, predicted to form β-hairpins but, interestingly, to lack the intramolecular disulfide bonds, cation-π or aromatic interactions that generally stabilize such AMP structures. Other examples include Ponericin Q42, Latarcin 4a, Kassinatuerin 1, Ceratotoxin D, and CPF-B1 peptide, which have α-helical folds, as well as mixed αβ folds of human Histatin 2 peptide and Garvicin A which are, to the best of our knowledge, the first linear αββ fold AMPs lacking intramolecular disulfide bonds. In addition to fold matches to experimentally derived structures, unique folds were also obtained, namely for Microcin M and Ipomicin. These results help in understanding the range of protein scaffolds that naturally bear antimicrobial activity and may facilitate protein design efforts towards better AMPs.
Online Inquiry
Verification code
Inquiry Basket